We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new tre... Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. Show more
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...
TAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development...
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show that will air as a sponsored program on Bloomberg TV on Saturday...
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Works' New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) ("Company"), a...
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging...
Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase New York...
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.26 | -6.03248259861 | 4.31 | 4.52 | 3.64 | 22803 | 4.10503811 | CS |
| 4 | -1.38 | -25.4143646409 | 5.43 | 5.5099 | 3.51 | 37031 | 4.30784295 | CS |
| 12 | -1.9 | -31.9327731092 | 5.95 | 7.52 | 3.51 | 32276 | 5.4820151 | CS |
| 26 | -2.95 | -42.1428571429 | 7 | 20.72 | 3.51 | 51606 | 7.37207836 | CS |
| 52 | -2.95 | -42.1428571429 | 7 | 20.72 | 3.51 | 51606 | 7.37207836 | CS |
| 156 | -2.95 | -42.1428571429 | 7 | 20.72 | 3.51 | 51606 | 7.37207836 | CS |
| 260 | -2.95 | -42.1428571429 | 7 | 20.72 | 3.51 | 51606 | 7.37207836 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
